This finding is not readily translatable to results from post mortem lesion staging that suggest an earlier tau deposition [6] but they do appear to conflict with formulations suggesting that initial CSF Aβ42 reductions drive the AD cascade in late onset AD [36]. The gene discussed is MAPT; the disease is Alzheimer disease.